Histone Demethylases

N-Benzylideneaniline is a selective inhibitor of xylinostilbene-α,β-dioxygenase (LSD), a key enzyme involved in the oxidative degradation of lignin. This compound exhibits significant biological activity in influencing lignin metabolism, making it valuable for studies on lignocellulosic biomass conversion. Its applications extend to research focusing on environmental biochemistry and the enzymatic processes governing plant biomass degradation.

INCB059872 is a potent and selective irreversible inhibitor of Lysine-Specific Demethylase 1 (LSD1). This compound demonstrates strong biological activity in the modulation of histone methylation, making it a valuable tool for investigating epigenetic regulation. INCB059872 is particularly relevant for research applications focused on myeloid leukemia and other hematological malignancies, providing insights into therapeutic strategies targeting LSD1-dependent pathways.

LSD1-IN-14 is a potent and selective inhibitor of Lysine-specific demethylase 1 (LSD1), exhibiting an IC50 of 0.89 μM. This compound effectively inhibits the proliferation of A549 lung cancer cells and THP-1 monocytic cells, while also inducing apoptosis in tumor cell lines. LSD1-IN-14 is valuable for research applications focused on understanding the role of LSD1 in cancer biology and developing potential therapeutic strategies targeting epigenetic regulation.

TPC-144 is an inhibitor of LSD1/KDM1A, targeting the demethylation process by reducing DNMT1 protein levels, resulting in decreased methylation of LINE-1 elements. This compound has shown promising synergistic effects with Decitabine, enhancing DNA demethylation, which promotes differentiation and apoptosis in leukemia cells. Furthermore, TPC-144 has demonstrated anti-tumor activity in acute myeloid leukemia (AML) models, making it a valuable tool for AML research and therapeutic studies.

LSD1/HDAC-IN-2 is a potent inhibitor of lysine-specific demethylase 1 (LSD1) and several histone deacetylases (HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8), with IC50 values ranging from 1.0 to 39.0 nM. This compound demonstrates significant biological activity by inhibiting the proliferation of colorectal cancer cells, inducing apoptosis, and causing G2/M cell cycle arrest. Additionally, LSD1/HDAC-IN-2 reduces cell migration and displays antitumor efficacy in mouse models, making it a valuable tool for cancer research and therapeutic development.

LSD1-IN-25 is a potent and selective inhibitor of lysine-specific demethylase 1 (LSD1), demonstrating an IC50 of 46 nM and a Ki of 30.3 nM. This compound effectively induces apoptosis in cancer cells, making it a valuable tool for investigating the role of LSD1 in cancer biology and therapeutic applications. Its oral bioavailability further supports its use in preclinical studies aimed at targeting epigenetic regulation in malignancies.

PROTAC KDM4 Degrader-1 is a potent proteolysis targeting chimera (PROTAC) designed to selectively degrade KDM4A-C while sparing KDM4D. This compound demonstrates significant antiproliferative effects in esophageal cancer cells, inducing apoptosis and cell cycle arrest. Additionally, PROTAC KDM4 Degrader-1 effectively inhibits histone H3 lysine demethylation, making it a valuable tool for research into cancer biology and epigenetic regulation.